NASDAQ:VRDN

Viridian Therapeutics Q1 2025 Earnings Results & Report

Viridian Therapeutics logo
$30.06 +0.26 (+0.87%)
Closing price 04:00 PM Eastern
Extended Trading
$30.06 0.00 (-0.02%)
As of 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viridian Therapeutics beat analyst earnings expectations but missed on revenue in its Q1 2025 results, released May 6, 2025. The company reported EPS of -$0.87 versus the -$0.95 consensus estimate, while revenue of $70 thousand fell short of the $160 thousand estimate by $90 thousand.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Viridian Therapeutics EPS Results

Actual EPS
-$0.87
Consensus EPS
-$0.95
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Viridian Therapeutics Revenue Results

Actual Revenue
$70 thousand
Expected Revenue
$160 thousand
Beat/Miss
Missed by -$90.00 thousand
YoY Revenue Growth
N/A

Viridian Therapeutics Q1 2025 Earnings FAQ

Viridian Therapeutics (NASDAQ:VRDN) reported earnings of -$0.87 per share for Q1 2025, beating the consensus estimate of -$0.95. The report was announced on Tuesday, May 6, 2025.

Viridian Therapeutics reported revenue of $70 thousand for Q1 2025, against a consensus estimate of $160 thousand.

Viridian Therapeutics Earnings Headlines

Last call for your free 0DTE report
The 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for $29.97, but it's available as a free download for a limited time.tc pixel
See More Viridian Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Viridian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viridian Therapeutics and other key companies, straight to your email.

About Viridian Therapeutics

Viridian Therapeutics (NASDAQ:VRDN) is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes.

The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration. These candidates remain investigational.

Viridian’s roots include Miragen Therapeutics, which adopted the Viridian Therapeutics name in 2021. The company conducts clinical development to evaluate its potential treatments; its candidates are not approved medicines.

View Viridian Therapeutics Profile